A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03914625 |
Recruitment Status :
Suspended
(Other - FDA Partial Clinical Hold)
First Posted : April 16, 2019
Last Update Posted : January 12, 2023
|
Sponsor:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
National Cancer Institute (NCI)
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Suspended |
---|---|
Estimated Primary Completion Date : | September 30, 2029 |
Estimated Study Completion Date : | September 30, 2029 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):